Landec Corp. (NASDAQ:LNDC) was down 2.1% during trading on Thursday . The stock traded as low as $10.55 and last traded at $10.63, with a volume of 88,324 shares. The stock had previously closed at $10.86.

Several equities research analysts recently commented on LNDC shares. Maxim Group began coverage on Landec Corp. in a report on Tuesday, June 7th. They set a “buy” rating and a $16.00 target price on the stock. Zacks Investment Research upgraded shares of Landec Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, June 7th. Finally, Wedbush began coverage on shares of Landec Corp. in a research report on Thursday, July 7th. They issued a “neutral” rating and a $12.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $15.10.

The stock’s market cap is $287.79 million. The firm has a 50-day moving average of $11.01 and a 200-day moving average of $11.03.

An institutional investor recently raised its position in Landec Corp. stock. Heartland Advisors Inc. raised its position in shares of Landec Corp. (NASDAQ:LNDC) by 5.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 936,452 shares of the company’s stock after buying an additional 52,509 shares during the period. Heartland Advisors Inc. owned 3.46% of Landec Corp. worth $11,078,000 at the end of the most recent reporting period.

Landec Corporation designs, develops, manufactures and sells differentiated products for food and biomaterials markets and licenses technology applications to partners. The Company’s segments include Food Products Technology, Food Export and Hyaluronan-based Biomaterials. The Company’s Food Products Technology segment markets and packs specialty packaged whole and fresh-cut fruit and vegetables.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.